UCB Pharma SpA

Brief Description: UCB is a biopharmaceutical company with headquarters in Belgium, in Brussels and with an Italian headquarters in Milan, focused on developing innovative solutions to transform the lives of people living with severe immunological and neurological diseases.

Company Overview: UCB is a biopharmaceutical company with headquarters in Belgium, in Brussels and with an Italian headquarters in Milan, focused on developing innovative solutions to transform the lives of people living with severe immunological and neurological diseases. With over 8,600 employees in around 40 countries, in 2021 the company generated revenues of 5.8 billion euros, for the eighth consecutive year in constant growth. UCB strongly promotes sustainable and continuous innovation. As proof of this, in 2021 it invested around 28% of its turnover in Research and Development, thanks to its 3 state-of-the-art research centers in Braine-l'Alleud in Belgium, in Slough, in the United Kingdom and in Boston, in the United States, as well as its network of integrated research and development centers around the world and numerous world-class scientific partnerships, both academically and with other biotech companies.

Why Federated Innovation?: UCB PHARMA S.P.A.’s corporate scope as currently carried out in Italy and worldwide is the research, development and commercialization of innovative pharmaceutical and biotechnology products. We continually innovate for patients. We are fully aligned with the Federated Innovation “Manifesto” promoting the Diversity, Equity and Inclusion, encouraging agile innovation and digitalization.